• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City

    7/1/21 8:54:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RXRX alert in real time by email

    SALT LAKE CITY, July 1, 2021 /PRNewswire/ -- Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that it is doubling the size of its headquarters at The Gateway in downtown Salt Lake City, signing a new lease with Vestar for an additional 100,000 square feet. The Gateway is a mixed-use lifestyle and entertainment district, featuring 1.2 million square feet of retail, dining and office space as well as 1,200 multifamily units.

    Recursion Logo (PRNewsfoto/Recursion)

    Recursion originally signed a lease in 2018 for 100,000 square feet at The Gateway, where it currently has over 250 employees. The company is expected to expand into its new space in the second quarter of 2022.

    "Recursion is a pioneer in the emerging field of technology-enabled drug discovery. To deliver on our mission we have grown our world-class team of scientists, engineers, clinicians and company builders by more than 60% in the last year," said Recursion President and COO Tina M. Larson. "Expanding our laboratory footprint will allow us to grow our proprietary biological dataset even faster and add several novel capabilities in biology and chemistry research."

    Recursion's expansion comes after the formation of BioHive, a new public-private collaboration that will expand business development in Utah's growing healthcare innovation sector. BioHive serves as the brand representing Utah's healthcare innovation community, of which Salt Lake City is the hub, supporting some of the greatest entrepreneurs and companies in the country. Leaders from these companies have joined up with local economic development and industry backers to represent more than 1,000 Utah companies in the biopharmaceuticals, medical devices, diagnostics, genomics, biotechnology, health tech, and digital informatics fields. The Gateway sits at the epicenter of BioHive.

    "Recursion is a tremendous partner for Salt Lake City on numerous fronts," said Clark Cahoon, with Salt Lake City Department of Economic Development. "Their continued success in the healthcare innovation ecosystem comes as no surprise with their dedication to improving lives. We applaud this expansion at The Gateway and could not be happier to have Recursion expand their footprint in downtown Salt Lake City."

    "As Life Science Companies continue to grow in Salt Lake City and throughout the United States, our mixed-use retail centers are the perfect fit for their innovative workers who crave culture and the lifestyle our tenant mix provides," said Vestar Vice President of Leasing Jenny Cushing. "We have seen tremendous growth in the Salt Lake City economy as civic leaders and executives continue to position the area as a top location for a diverse spectrum of businesses. We will continue to look for ways to innovate and attract businesses that bring the community together at our center."

    Built in 2001 and situated on 21 acres, The Gateway is located at the intersection of 400 West and South Temple. The center is home to Salt Lake City's largest outdoor art gallery and hosts nearly 400 events per year. The center is leased to several companies including Dave & Buster's, Clark Planetarium, HallPass, The Depot by Live Nation, Larry H. Miller Megaplex Theatre, Discovery Gateway Children's Museum, TruFusion, Fidelity Investments, Cicero and Kiln Co-Working.

    Vestar was represented in house by Jenny Cushing and by Andy Moffitt, Lance Pendleton and Troy Hardy with Mountain West Commercial Real Estate. Recursion was represented in-house.

    About Recursion

    Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering. Its goal is to radically improve the lives of patients and industrialize drug discovery. Central to this mission is the Recursion Operating System, which combines an advanced infrastructure layer to generate what it believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets. The Recursion OS is combined with the Recursion Map, a suite of custom software, algorithms and machine learning tools used to explore foundational biology unconstrained by human bias, and navigate to new biological insights. Learn more at www.recursion.com, or connect on Twitter and LinkedIn.

    About Vestar

    As one of the leading privately held real estate companies in the United States, Vestar acquires, develops and manages shopping and entertainment destinations that serve as community focal points. Since its inception in 1989, Vestar has earned a reputation for integrity and responsibility in the fields of retail property development, operations, leasing and marketing. Vestar's current portfolio of retail properties totals 30 million square feet throughout the western states. For more information, please visit vestar.com.

    Forward-Looking Statements

    This press release contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements provide our expectations or forecasts regarding future events. You can identify these statements by the fact they do not relate strictly to historical or current facts. They may use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, forward-looking statements include statements relating to intended future actions; plans with respect to clinical trials and preclinical activities; prospective products or product approvals; future performance or results of anticipated products or technology; expenses; our ability to obtain, maintain and enforce intellectual property protections and financial results; in addition to other topics. Any or all of our forward-looking statements here or elsewhere may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements and from expected or historical results. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. In particular, you should read the discussion in the "Risk Factors" section in our Prospectus filed with the U.S. Securities and Exchange Commission (SEC) on April 16, 2021 and in our periodic filings with the SEC. Other factors besides those listed could also adversely affect the company. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future developments or otherwise, except to the extent required by applicable law. These forward-looking statements (except as may be otherwise noted) speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. You are advised to consult any further disclosures we make on related subjects in our reports to the SEC.

    Press Contact

    Elyse Freeman - Communications and Content Manager

    [email protected]  

    Investor Relations Contact

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/recursion-signs-lease-with-vestar-for-an-additional-100-000-sf-of-space-at-the-gateway-in-downtown-salt-lake-city-301323893.html

    SOURCE Recursion

    Get the next $RXRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RXRX

    DatePrice TargetRatingAnalyst
    12/17/2025$11.00Neutral → Overweight
    Analyst
    7/3/2025$5.00Equal-Weight
    Morgan Stanley
    5/22/2023$8.00Equal-Weight
    Morgan Stanley
    3/16/2023$17.00Buy
    Needham
    9/16/2022$20.00Overweight
    KeyBanc Capital Markets
    4/18/2022$10.00Buy → Neutral
    BofA Securities
    3/4/2022$32.00 → $10.00Outperform → Market Perform
    SVB Leerink
    12/8/2021$30.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Khan Najat was granted 1,703,892 shares and covered exercise/tax liability with 10,364 shares, increasing direct ownership by 277% to 2,304,663 units (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    2/10/26 6:18:29 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Taylor Ben R was granted 470,533 shares and covered exercise/tax liability with 11,400 shares, increasing direct ownership by 60% to 1,220,683 units (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    2/10/26 6:18:20 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Scientific Officer Hallett David was granted 526,318 shares and covered exercise/tax liability with 11,400 shares, increasing direct ownership by 87% to 1,109,059 units (SEC Form 4)

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    2/10/26 6:18:12 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

    Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 820,431 shares of its class A common stock in the aggregate to 17 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the "2024 Plan"). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4). Each inducement

    2/12/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AI, Genomics, and CRISPR Signal a New Phase of Biological Innovation

    DENVER, Feb. 10, 2026 (GLOBE NEWSWIRE) -- As artificial intelligence continues to move beyond software and automation, its impact on genomics and gene editing is becoming increasingly tangible. Recent developments among genomics and AI-enabled biotechnology companies suggest that AI-driven pattern recognition is emerging as a foundational layer for CRISPR-based innovation, with implications spanning human health and advanced biologically assembled materials. Illumina (NASDAQ:ILMN), the global leader in DNA sequencing, recently secured U.S. Medicare reimbursement for its TruSight™ Oncology Comprehensive test, expanding access to broad genomic profiling in routine cancer care. Increased rei

    2/10/26 9:29:10 AM ET
    $GH
    $ILMN
    $RXRX
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift

    Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 trillion in 2026 as the entire healthcare ecosystem ditched trial-and-error medicine for AI-native diagnostic precision and autonomous operations[1]. This massive movement has pushed the AI drug discovery sector to $1.81 billion, powered by "federated learning" models that use high-frequency sensing to collapse development timelines from years into months[2]. This new Diagnostic Data Core is creating massive tailwinds for VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Recursion Pharmaceutical

    1/29/26 9:25:00 AM ET
    $LLY
    $RXRX
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Computer Software: Programming Data Processing

    $RXRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Recursion Pharmaceuticals Inc.

    SCHEDULE 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    2/5/26 10:04:18 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Recursion Pharmaceuticals Inc.

    144 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    1/20/26 11:26:02 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

    1/12/26 8:21:15 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Recursion Pharmaceuticals upgraded by Analyst with a new price target

    Analyst upgraded Recursion Pharmaceuticals from Neutral to Overweight and set a new price target of $11.00

    12/17/25 8:47:25 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley resumed coverage on Recursion Pharmaceuticals with a new price target

    Morgan Stanley resumed coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $5.00

    7/3/25 7:50:07 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

    Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00

    5/22/23 7:50:41 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Financials

    Live finance-specific insights

    View All

    Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

    Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 financial results on Wednesday, November 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on November 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.About RecursionR

    10/28/25 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

    Salt Lake City, UT, July 29, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the financial markets.Recursion will host a (L)earnings Call on August 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/pEH9b7wv2RxbrFDR7.Ab

    7/29/25 8:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

    Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

    7/8/25 8:00:00 AM ET
    $RLYB
    $RXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $RXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

    Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026: Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and a Board Member, will succeed Co-Founder and CEO Chris Gibson, Ph.D., as Chief Executive Officer and President. Najat will also continue in her role as a member of the Board of Directors.  Chris Gibson, Ph. D., current Co-Founder and CEO, will transition to Chairman of the Board of Directors and an interim Executive Adv

    11/5/25 6:28:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

    Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the

    3/18/25 8:00:00 AM ET
    $DVAX
    $RXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Altitude Lab Startups Raise $154M in Capital

    SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community.In addition, Altitude Lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, Ph.D., CEO and founder of Elnora AI. The fellowship provides early-career scientists with up to $150,000 in funding, scientific support, and mentorship to accelerate the growth of their sta

    2/18/25 11:00:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/12/24 4:57:06 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/12/24 10:34:18 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

    SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

    11/4/24 4:16:21 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care